Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Actavis Inc    

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 14 821 M
EBIT 2016 7 602 M
Net income 2016 -
Debt 2016 17 680 M
Yield 2016 -
Sales 2017 16 183 M
EBIT 2017 8 713 M
Net income 2017 215 M
Debt 2017 14 285 M
Yield 2017 -
P/E ratio 2016 8,42
P/E ratio 2017 426,21
EV / Sales2016 7,57x
EV / Sales2017 6,72x
Capitalization 94 506 M
More Financials
Company
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products.The firm offers products under the following brands: BOTOX, Juvederm, Linzess, Namenda, Restasis, Latisse, Teflaro, Lo Loestrin Fe, Bystolic, DORYX, Saphris, Fetzima, Namenda XR, Namzaric, Viberzi,... 
Sector
Pharmaceuticals
Calendar
11/02Earnings Release
More about the company
Surperformance© ratings of Actavis Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACTAVIS INC
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/14DJAllergan to Buy Vitae Pharmaceuticals for $639 Million
09/08 BAYER EXPLORING SALE OF DERMATOLOGY : Bloomberg
09/07 EXCLUSIVE - GW PHARMACEUTICALS HIRES : sources
08/30 U.S. slams EU, but Apple tax demand first issued in Washington
08/29DJMondelez Walks Away After Hershey Spurns Raised Bid
08/24DJPfizer Buys Part of AstraZeneca's Antibiotics Business
08/09DJBotox Maker Allergan's Revenue Climbs, but Loss More Than Doubles -- WSJ
08/08DJAllergan Revenue Increases, Though Loss Widens--Update
08/08DJMARKET SNAPSHOT : Stocks Back Off All-time Highs As Health-care Stocks Slump
More news
Sector news : Pharmaceuticals - NEC
09/27DJPFIZER : Scraps Plan to Break Up Company -- WSJ
09/26DJMYLAN : EpiPen Pretax Profits 60% Higher Than Number Told to Congress -- 3rd Upd..
09/26 MYLAN : faces scrutiny over EpiPen profit data shown to Congress
09/26DJPFIZER : Throws Out Plan to Split Into Two Companies -- 2nd Update
09/26DJPfizer Throws Out Plan to Split Into Two Companies
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 299 $
Spread / Average Target 25%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Brenton L. Saunders President, Chief Executive Officer & Director
Paul M. Bisaro Executive Chairman
Robert A. Stewart Chief Operating Officer
Maria Teresa Hilado Chief Financial Officer
C. David Nicholson Chief Research & Development Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACTAVIS INC94 506
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
More Results